JP7685985B2 - アルツハイマー病の処置のための中和抗アミロイドベータ抗体 - Google Patents

アルツハイマー病の処置のための中和抗アミロイドベータ抗体 Download PDF

Info

Publication number
JP7685985B2
JP7685985B2 JP2022502422A JP2022502422A JP7685985B2 JP 7685985 B2 JP7685985 B2 JP 7685985B2 JP 2022502422 A JP2022502422 A JP 2022502422A JP 2022502422 A JP2022502422 A JP 2022502422A JP 7685985 B2 JP7685985 B2 JP 7685985B2
Authority
JP
Japan
Prior art keywords
binding
binding polypeptide
soluble
antibody
exemplary embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022502422A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541459A5 (enExample
JP2022541459A (ja
Inventor
ミン・ジン
ローラン・プラディエ
デーヴィッド・レセック
デニス・セルケ
タラ・トラヴァリン
ドミニク・ウォルシュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Brigham and Womens Hospital Inc
Original Assignee
Sanofi SA
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA, Brigham and Womens Hospital Inc filed Critical Sanofi SA
Publication of JP2022541459A publication Critical patent/JP2022541459A/ja
Publication of JP2022541459A5 publication Critical patent/JP2022541459A5/ja
Application granted granted Critical
Publication of JP7685985B2 publication Critical patent/JP7685985B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2022502422A 2019-07-16 2020-07-15 アルツハイマー病の処置のための中和抗アミロイドベータ抗体 Active JP7685985B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962874724P 2019-07-16 2019-07-16
US62/874,724 2019-07-16
PCT/US2020/042161 WO2021011673A2 (en) 2019-07-16 2020-07-15 Neutralizing anti-amyloid beta antibodies for the treatment of alzheimer's disease

Publications (3)

Publication Number Publication Date
JP2022541459A JP2022541459A (ja) 2022-09-26
JP2022541459A5 JP2022541459A5 (enExample) 2023-07-24
JP7685985B2 true JP7685985B2 (ja) 2025-05-30

Family

ID=71895293

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022502422A Active JP7685985B2 (ja) 2019-07-16 2020-07-15 アルツハイマー病の処置のための中和抗アミロイドベータ抗体

Country Status (6)

Country Link
EP (1) EP3999532A2 (enExample)
JP (1) JP7685985B2 (enExample)
KR (1) KR20220034857A (enExample)
CN (3) CN121800915A (enExample)
CA (1) CA3147239A1 (enExample)
WO (1) WO2021011673A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3658172A4 (en) 2017-07-25 2021-05-05 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND HIS LIGAND
CN113711036B (zh) 2019-01-30 2025-03-18 真和制药有限公司 抗gal3抗体及其用途
CN116157151A (zh) 2020-05-26 2023-05-23 真和制药有限公司 通过阻断半乳凝素-3治疗炎性疾病的方法
WO2026082154A1 (en) * 2024-10-18 2026-04-23 Lepu Biopharma Co., Ltd. Anti-beta amyloid antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508072A (ja) 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1994009817A1 (en) 1992-11-04 1994-05-11 City Of Hope Novel antibody construct
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
WO1997014719A1 (en) 1995-10-16 1997-04-24 Unilever N.V. A bifunctional or bivalent antibody fragment analogue
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
WO2002002781A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Heterodimeric fusion proteins
US20160213794A1 (en) * 2002-10-01 2016-07-28 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules and uses thereof
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
CN101198698B (zh) 2005-03-31 2014-03-19 中外制药株式会社 通过调节多肽缔合制备多肽的方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PE20090329A1 (es) * 2007-05-30 2009-03-27 Abbott Lab Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
DK2170389T3 (en) * 2007-06-12 2015-01-19 Ac Immune Sa Humanized antibodies against amyloid beta
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US9272030B2 (en) * 2007-10-17 2016-03-01 Janssen Sciences Ireland Uc Use of tau to monitor immunotherapy
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
WO2010054007A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP2593475B1 (en) * 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
EP2906597B1 (en) * 2012-10-15 2020-04-08 Medimmune Limited Antibodies to amyloid beta

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006508072A (ja) 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAYED, Rakez et al.，Science，2003年，Vol. 300, No. 5618，p.486-489，DOI: 10.1126/science.1079469
RYAN, Deborah A. et al.，Journal of Neuroscience Methods，2010年，Vol. 190, No. 2，p.171-179，DOI: 10.1016/j.jneumeth.2010.05.001
YING, Zhang et al.，Hybridoma，2009年，Vol. 28, No. 5，p.349-354，DOI: 10.1089/hyb.2009.0015

Also Published As

Publication number Publication date
EP3999532A2 (en) 2022-05-25
CN115175932B (zh) 2025-10-31
WO2021011673A3 (en) 2021-07-01
KR20220034857A (ko) 2022-03-18
CN115175932A (zh) 2022-10-11
US20230107034A1 (en) 2023-04-06
CN121949538A (zh) 2026-05-01
CN121800915A (zh) 2026-04-07
JP2022541459A (ja) 2022-09-26
WO2021011673A2 (en) 2021-01-21
CA3147239A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
JP7608404B2 (ja) シヌクレイノパチーの治療のための薬剤、使用および方法
AU2022252753B2 (en) ANTIBODIES TO a-SYNUCLEIN AND USES THEREOF
US10364286B2 (en) Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
TWI741987B (zh) 特異性針對過度磷酸化τ蛋白之抗體及其使用方法
KR102952441B1 (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도
CN107074965B (zh) 特异性结合微管相关蛋白tau的抗体和抗原结合片段
JP7623699B2 (ja) タウ認識抗体
AU2008334637B2 (en) Antigen binding proteins
JP2022169598A (ja) タウ認識抗体
JP2020109103A (ja) タウ免疫療法
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
WO2018161872A1 (zh) 抗b7-h3抗体、其抗原结合片段及其医药用途
CA2723219A1 (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
JP2019529336A (ja) 過リン酸化タウに特異的な抗体およびその使用方法
RS61717B1 (sr) Poboljšana antitela koja vezuju a-beta protofibril
WO2018219327A1 (zh) 抗cd40抗体、其抗原结合片段及其医药用途
CN115697393A (zh) 抗PHF-tau抗体及其用途
WO2019001559A1 (zh) 抗gitr抗体、其抗原结合片段及其医药用途
US12630615B2 (en) Neutralizing anti-amyloid beta antibodies for the treatment of Alzheimer's disease
EP4259657A1 (en) Anti-amyloid beta antibodies and methods of using the same
CA2990555C (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230713

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230713

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240904

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250409

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250513

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250520

R150 Certificate of patent or registration of utility model

Ref document number: 7685985

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150